JAGADISHWAR PHARMACEUTICAL WORKS LIMITED
CIN : L24232WB1987PLC281952

21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053
Website: https://jagadishwarpharma.com
E_mail ID: jpwltd@yahoo.com
Phone No.: +91 9163513015

August 10, 2026

Head- Listing & Compliance
Metropolitan Stock Exchange of India Ltd. (MSEI),
205(A), 2nd Floor,
Piramal Agastya Corporate Park,
Kamani Junction, LBS Road,
Kurla (West),
Mumbai – 400 070

Subject: Outcome of Board Meeting held on August 10, 2026- Unaudited Financial Results for the quarter ended June 30, 2026.

Dear Sir,

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Board of Directors at their meeting held today, August 10, 2026 at the registered office of the Company inter alia have transacted the following items:

1. The Board considered and approved the Unaudited financial results of the Company for the quarter ended June 30, 2026. Copies of the Unaudited Financial Results along with Limited review report for your reference and records in **Annexure 1**

2. Approval change in Designation of Sandip Kumar Singh (DIN: 08443518) from Independent Director to Non- Independent Non- Executive Director.

The Board of Directors, based on the recommendation of the Nomination and Remuneration Committee approve the change in designation of Sandip Kumar Singh (DIN: 08443518) as from an Independent Director to Non- Independent Non-Executive Director of the Company with effect from August 10, 2026

The relevant details as required under Regulation 30 read with Schedule III Para A of Part A of the SEBI Listing Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFDPoD1/P/CIR/2023/123 dated 13th July 2023 and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is provided in **Annexure 2**

The Board Meeting commenced at 02.00 p.m. and concluded at 02.30 p.m. The above information will also be hosted on the Company's website https://jagadishwarpharma.com.

We request you to kindly take note of the same.

Thanking You,

Yours faithfully,
For Jagadishwar Pharmaceutical Works Limited

SANDIP KUMAR SINGH

Digitally signed by SANDIP KUMAR SINGH
Date: 2026.08.10 14:36:16 +05'30'

(SANDIP KUMAR SINGH)
Director
DIN: 08443518

Encl.: A/a

Jagadishwar Pharmaceutical Works Limited

(CIN : L24232WB1987PLC281952)

Regd. Office: 21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053

Email ID: jpwltd@yahoo.com **Website:** jagadishwarpharma.com **Tel:** +91 9163513015

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.26	31.03.26	30.06.25	31.03.26
		Unaudited	Audited	Unaudited	Audited
1	**Income From Operations**				
	(a) Net Sales / Income from Operations	-	-	-	5.981
	(b) Other Operating Income	11.863	10.676	9.077	37.775
	Total Income from Operations	**11.863**	**10.676**	**9.077**	**43.756**
2	**Expenses**				
	(a) Cost of materials consumed	-	-	-	-
	(b) Purchase of stock-in-trade	-	-	-	-
	(c) Changes in inventories of finished goods, work-	-	-	-	5.981
	(d) Employee benefits expense	0.591	0.593	7.319	28.913
	(e) Depreciation and amortisation expense	0.016	0.061	-	0.061
	(f) Finance Cost	-	-	-	-
	(g) Other expenses	3.949	1.064	4.175	7.782
	Total Expenses	**4.556**	**1.719**	**11.494**	**42.737**
3	**exceptional items (1-2)**	**7.306**	**8.958**	**(2.418)**	**1.019**
4	Other Income	-	-	-	-
5	**Profit / (Loss) from ordinary activities before finance costs and exceptional items (3-4)**	**7.306**	**8.958**	**(2.418)**	**1.019**
6	Finance Costs	-	-	-	-
7	**Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6)**	**7.306**	**8.958**	**(2.418)**	**1.019**
8	Exceptional Items	-	-	-	-
9	**Profit / (Loss) from ordinary activities before tax (7-8)**	**7.306**	**8.958**	**(2.418)**	**1.019**
10	Tax Expense	1.183	0.161	-	0.161
11	**Net Profit / (Loss) from ordinary activities after tax (9-10)**	**6.124**	**8.797**	**(2.418)**	**0.858**
12	Extraordinary itesm (net of tax Rs. Nil Lakhs)	-	-	-	-
13	**Net Profit / (Loss) for the period (11-12)**	**6.124**	**8.797**	**(2.418)**	**0.858**
14	Share of Profit / (loss) of associates	-	-	-	-
15	Minority Interest	-	-	-	-
16	**Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13-14-15)**	**6.124**	**8.797**	**(2.418)**	**0.858**
17	Other Comprehensive Income	-	8.080	-	8.080
18	**Total Comprehensive Income**	**6.124**	**16.877**	**(2.418)**	**8.938**
19	**Paid-up Equity Share Capital (Face Value of Rs.10/- per Share)**	**2,970.02**	**2,970.02**	**2,970.02**	**2,970.02**
20	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	132.34
21.i	**Earnings Per Share (before extraordinary items) (of Rs. 10/- each) (not annualised)**				
	(a) Basic	0.02	0.06	-	0.03
	(b) Diluted	0.02	0.06	-	0.03
21.ii	**Earnings Per Share (after extraordinary items) (of Rs. 10/- each) (not annualised)**				
	(a) Basic	0.02	0.06	-	0.03
	(b) Diluted	0.02	0.06	-	0.03

Notes :

1. The figures for the corresponding previous periods have been restated / regrouped, wherever necessary, to make them comparable.
2. These results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules,2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable .
3. The Audit Committee reviewed the above results. The Board of Directors at its meeting held on 10th August, 2026, approved the above results. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
4. The Company does not have any reportable segment as per Indian Accounting Standard "Operating Segment" (Ind AS-108). Accordingly, segment reporting is not applicable.

For Jagadishwar Pharmaceuticals Works Ltd.

Swapan Sarkar

Swapan Sarkar

Director

(DIN : 05149442)

Date : 10/08/2026

Place: Kolkata

RAJESH U SHAH & ASSOCIATES
Chartered Accountants

235, Bansdroni Place
Kolkata-700070
Phone : 033-24310375
E-Mail: rs97cal1@rediffmail.com

Review report to Jagadishwar Pharmaceutical Works Limited

We have reviewed the accompanying statement of unaudited financial results of Jagadishwar Pharmaceutical Works Limited (Name of the Company) for the period ended 30th June 2026. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For **Rajesh U Shah & Associates**
Chartered Accountants

Rajesh Shah

Rajesh Shah
Proprietor
Membership Number: 056550
Firm Regn. No.: 327799E
UDIN: 26056550YRCFZM1154

RAJESH U SHAH & ASSOCIATES KOLKATA Chartered Accountants

Place: Kolkata
Date: August 10, 2026

JAGADISHWAR PHARMACEUTICAL WORKS LIMITED

CIN : L24232WB1987PLC281952

21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053
Website: https://jagadishwarpharma.com
E_mail ID: jpwltd@yahoo.com
Phone No.: +91 9163513015

Annexure 2

1. **Change in Designation of Sandip Kumar Singh from (Independent Director to Non-Independent & Non-Executive Director)**

Sr no	Particulars	Details
1	Name	Sandip Kumar Singh
2	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Designation of Mr. Sandip Kumar Singh from the Independent Director to Non- Independent Non-Executive Director.
3	Date of re-designation appointment/ re-appointment/ cessation (as applicable) & term of appointment/ re-appointment	August 10, 2026
4	Term	Not Applicable
5	Brief Profile (in case of appointment)	10 years Accountants experience
6	Disclosure of relationships between Directors	Not Applicable
7	Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/2018/02 dated June 20, 2018 issued by the BSE and NSE, respectively	Sandip Kumar Singh is not debarred from holding the office of Director by virtue of any SEBI Order or any other such authority